Tic disorders can be improved by administering theanine, an amino acid that crosses the blood-brain barrier, or a dipeptide consisting of theanine and a different amino acid. In addition, these compositions can be added to foods and drinks or pharmaceuticals.
Glutamine or glutamine-containing dipeptide in a specific dosage for the treatment of inflammation
申请人:Biotempt B.V.
公开号:EP2106791A1
公开(公告)日:2009-10-07
Described are methods of treating or preventing an inflammation by administering to a patient in need thereof a pharmacologic dose of glutamine or a glutamine-containing dipeptide in a pharmaceutically acceptable carrier, wherein said dose is selected from a range of 0.09 to 90mg glutamine per kg bodyweight of the patient.
Compositions and methods for improving skin health and for the treatment and prevention of diseases, disorders and conditions associated with pathogenic microbes
申请人:DermBiont, Inc.
公开号:US11040077B2
公开(公告)日:2021-06-22
Disclosed herein are compositions and methods for using human-derived Janthinobacterium lividum. Compositions improve skin health. Methods may include applying human-derived Janthinobacterium lividum over a host or host area, such as skin or mucosa, to minimize the presence of one or more microbes, maximize therapeutic effects, and/or improve health. A method to minimize a pathogenic microbe may include applying to a surface a composition including human-derived Janthinobacterium lividum and an acceptable carrier. Compositions and methods may include a prebiotic to maximize growth and/or metabolites. Compositions and methods may include human-derived Janthinobacterium lividum metabolites, such as violacein, prodigiosin, indole-3-carboxaldehyde, and lantibiotics, and/or other Postbiotics.
A method of treating a problem relating to tissue metabolism by administering to a patient in need a single dose of glutamine in a pharmaceutically acceptable carrier. Also provided is glutamine for the treatment of an injury relating to tissue metabolism and for preventing cardiac cell damage. A therapeutic composition for treating and preventing cellular metabolic injury, preventing cardiac cell damage, and increasing heat shock protein expression where in the therapeutic includes a single dose of glutamine in a pharmaceutically acceptable carrier is also provided. A method of increasing the expression of heat shock proteins by administering a single dose of glutamine in a pharmaceutically acceptable carrier to a location in need is further provided.